Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
QD Clinic - CREST or More?
Is this CREST or Diffuse PSS?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/h7e2tcOaaF https://t.co/6AceRXb4Nq
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - CREST or More?
Is this CREST or Diffuse PSS?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/eA1GijHiYu https://t.co/3EmN9WAyIR
Dr. John Cush @RheumNow( View Tweet )
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/AEJmW95vud https://t.co/3NnKjHQJtv
Dr. John Cush @RheumNow( View Tweet )
post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8 https://t.co/tB9sd9VS1K
Dr. John Cush @RheumNow( View Tweet )
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/Cbzi00xHdb https://t.co/JLSIyOdxKb
Dr. John Cush @RheumNow( View Tweet )
ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
Best of 2024: BSR Guidelines for Systemic Sclerosis Management
The British Society for Rheumatology has updated its 2015 guidelines for the management of patients with systemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
Read Article
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/XYeMl6ag9c https://t.co/ycM573lUGT
Dr. John Cush @RheumNow( View Tweet )
How do you manage skin in Sscl?
-RNA pol III + high risk for skin progression.
-Limited+ low risk + stable Sscl no need for immunesuppresors.
-Look for EF in pts with generalized morphea.
-Ttnt of skin depending on other organ involvements.
-If no Raynaud’s/hands spared think of… https://t.co/DZzhShKzS8 https://t.co/J9Qg1Lk2Wl
Dr. John Cush @RheumNow( View Tweet )
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/AsZ9CU2TZU https://t.co/TP1TMqotqi
Dr. John Cush @RheumNow( View Tweet )
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/OC7jNHdFMn https://t.co/cCCO70Xzoh
Dr. John Cush @RheumNow( View Tweet )
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
When should you consider off-label use of JAKi?
Read Article
What Lies Beneath: Understanding Nailfold Capillaroscopy
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold
Read Article
⏩Lecture by Prof Takeuchi on Sjogren Syndrome. Anti-centromere ab is seen in 10% of primary Sjogren syndrome. more likely to have sclerodactyly. https://t.co/mVry2OaNmq @IRACON24Blr https://t.co/SZlWQDpx8B
Links:
Dr. Dinesh Khanna @sclerodermaUM( View Tweet )
ICYMI: Precision medicine in Ssc ILD? Yes!
-Watch and wait approach can cause irreversible lung damage.
-⬆️CRP: biomarker of response (predicts mortality)
-⬆️KL-6: biomarker of severity (predicts progression of fibrosis)
-FAPI-PET: can eval disease activity vs response to ttx.… https://t.co/bTepwrsuNN https://t.co/e6xjtuquka
Links:
Adela Castro @AdelaCastro222( View Tweet )
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq
Dr. John Cush @RheumNow( View Tweet )
The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD
It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis
@RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir
sheila @RHEUMarampa( View Tweet )
#Scleroderma #molecular #signatures in #skin predict long term outcomes
👇worst with inflammatory signature
This may have clinical and trial applicability
Nice work!
Abst0711 #ACR24 @RheumNow @ACRheum https://t.co/3CFxu6bACu
Janet Pope @Janetbirdope( View Tweet )
#PAH in #SSc still has a poor #prognosis
👎
Esp #ILD with PAH - a double whammy
But also
group 1 PAH
And
Some are unclassifiable ▶️also bad px
Need
Earlier detection
More interventions
?prevention
Abst#0678 #ACR24 @RheumNow @ACRheum @sclerodermaUM https://t.co/AEQsTC1pzQ
Links:
Janet Pope @Janetbirdope( View Tweet )
Lung ultrasound for ILD in SSc/IIM would be great, no radiation and by the bedside - but a lot of skill required to interpret in reality.
Maybe AI/computer vision can come to the rescue?
Some nice models @StanfordRheum - will be watching this space!
#ACR24 ABST1965 @RheumNow https://t.co/0uXBSVSE4c
David Liew @drdavidliew( View Tweet )
3D management of Sscl from @delgaldoFrances
-Time
-Severity
-Type of organ involvement
*Identify phenotypes: fibrotic vs vascular damage.
*Raynaud’s red flags: +ANA, puffy fingers, abn capillaroscopy.
*Early ttnt of of digital ulcers delays onset of PAH.
*High IFN-I =marker of… https://t.co/ByfuV0MJds https://t.co/GdRVwuRf4E
Links:
Adela Castro @AdelaCastro222( View Tweet )
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato
Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH
Encouraging data for JAKs in this disease; need proper trials
#ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
Links:
Mike Putman @EBRheum( View Tweet )
A#1693
Change in FVC @ W12 or 24 has progn value @ w52 in AI-ILD
Study SENSCIS (SSc) & INBUILD (SARD) trial PBO gps
SENSCIS: OR for ILD progression 1.9 @ w12, 2.5 @ w24
INBUILD: OR 2.2 @ w12 & w24
Early PFTs predict outcomes @ 1 yr, short trials may be feasible
#ACR24 @RheumNow https://t.co/8cICAeG0nr
Links:
Eric Dein @ericdeinmd( View Tweet )
Recent Blogs
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
